Multiple Myeloma Market is Expected to Surpass USD 53.52 Billion by 2031, Report

The multiple myeloma market size was valued at $19,666.74 million in 2021, and is projected to reach $53,521.76 million by 2031, registering a CAGR of 10.5% from 2022 to 2031.

Market Size By 2031 USD 53.5 billion
Growth Rate CAGR of 10.5%
Forecast period 2021 - 2031
Report Pages 411

𝑹𝒆𝒒𝒖𝒆𝒔𝒕 𝑺𝒂𝒎𝒑𝒍𝒆 𝑪𝒐𝒑𝒚 𝒐𝒇 𝒕𝒉𝒆 𝑹𝒆𝒑𝒐𝒓𝒕 𝑯𝒆𝒓𝒆-
https://www.alliedmarketresearch.com/request-sample/3725

𝐈𝐦𝐩𝐚𝐜𝐭 𝐨𝐟 𝐂𝐨𝐯𝐢𝐝-19 𝐨𝐧 𝐌𝐮𝐥𝐭𝐢𝐩𝐥𝐞 𝐌𝐲𝐞𝐥𝐨𝐦𝐚 𝐌𝐚𝐫𝐤𝐞𝐭:

The outbreak of COVID-19 had a negative effect on the global multiple myeloma market, due to the social distancing rules which led to halt several clinical trials. Moreover, a lack of medical professionals, a lack of funding, and lockdowns have led to an increase in the number of patients who were unable to access timely treatments.

Furthermore, due to the disruption of the supply chain brought on by the pandemic, there were fewer medications available to treat multiple myeloma.

Also, R&D activities were severely impacted by the pandemic. The development of new therapies and treatments for multiple myeloma was also slowed down.

However, the global market for multiple myeloma has already recovered in the post-pandemic period.

𝐏𝐫𝐨𝐜𝐮𝐫𝐞 𝐂𝐨𝐦𝐩𝐥𝐞𝐭𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 (411+ 𝐏𝐚𝐠𝐞𝐬 𝐏𝐃𝐅 𝐰𝐢𝐭𝐡 𝐈𝐧𝐬𝐢𝐠𝐡𝐭𝐬, 𝐂𝐡𝐚𝐫𝐭𝐬, 𝐓𝐚𝐛𝐥𝐞𝐬, 𝐚𝐧𝐝 𝐅𝐢𝐠𝐮𝐫𝐞𝐬: https://www.alliedmarketresearch.com/multiple-myeloma-market/purchase-options

By drug type, the protease inhibitors segment contributed to more than one-third of the global multiple myeloma market revenue and is projected to rule the roost by 2031. The same segment would also portray the fastest CAGR of 11.1% throughout the forecast period. The segments such as chemotherapy, monoclonal antibody, and others are also studied in the report.

By end user, the hospitals segment accounted for the highest share in 2021, for nearly two-thirds of the global multiple myeloma market revenue and is expected to continue its lead during the forecast period. The same segment, however, would manifest the fastest CAGR of 10.7% throughout the forecast period. The clinics and others segments were also assessed in the study.

By disease type, the active multiple myeloma segment held the largest share in 2021, accounting for more than four-fifths of the global multiple myeloma market and would dominate the market in terms of revenue during the forecast period. The same segment would also cite the fastest CAGR of 10.6% throughout the forecast period. The smoldering multiple myeloma segment is discussed in the report.

𝐏𝐮𝐫𝐜𝐡𝐚𝐬𝐞 𝐈𝐧𝐪𝐮𝐢𝐫𝐲:
https://www.alliedmarketresearch.com/purchase-enquiry/3725

Key findings of the study

• By drug type, the protease inhibitor segment dominated the market in 2021.

• On the basis of disease type, the active multiple myeloma segment led the market in 2021.

• Depending on end user, hospitals was the prominent segment in 2021.

• Region wise, North America exhibited the highest growth in 2021, and is expected to grow during the forecast period.

𝐊𝐧𝐨𝐰 𝐌𝐨𝐫𝐞- https://www.alliedmarketresearch.com/multiple-myeloma-market

𝐓𝐫𝐞𝐧𝐝𝐢𝐧𝐠 𝐑𝐞𝐩𝐨𝐫𝐭𝐬 𝐢𝐧 𝐇𝐞𝐚𝐥𝐭𝐡𝐜𝐚𝐫𝐞 𝐈𝐧𝐝𝐮𝐬𝐭𝐫𝐲-
𝐂𝐥𝐞𝐚𝐧𝐫𝐨𝐨𝐦 𝐂𝐨𝐧𝐬𝐮𝐦𝐚𝐛𝐥𝐞𝐬 𝐦𝐚𝐫𝐤𝐞𝐭 https://www.alliedmarketresearch.com/cleanroom-consumables-market-A10926

𝐂𝐎𝐏𝐃 𝐚𝐧𝐝 𝐀𝐬𝐭𝐡𝐦𝐚 𝐃𝐢𝐚𝐠𝐧𝐨𝐬𝐭𝐢𝐜 𝐚𝐧𝐝 𝐌𝐨𝐧𝐢𝐭𝐨𝐫𝐢𝐧𝐠 𝐃𝐞𝐯𝐢𝐜𝐞𝐬 𝐌𝐚𝐫𝐤𝐞𝐭 https://www.alliedmarketresearch.com/copd-and-asthma-diagnostic-and-monitoring-devices-market-A10567

𝐆𝐥𝐨𝐯𝐞𝐬 𝐦𝐚𝐫𝐤𝐞𝐭 https://www.alliedmarketresearch.com/gloves-market-A08867

David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
Toll Free: +1-800-792-5285
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1-855-550-5975
Web: https://www.alliedmarketresearch.com

Alied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

This release was published on openPR.